Solid pharmaceutical compositions for treating HCV

US11246866B2 · kind B2 · utility

Assignee

• Abb Vie Inc. · US

Inventors

• Nancy E. Sever · Northbrook, US
• Ulrich Westedt · Schriesheim, DE
• Ute Lander · Dannenfels, DE
• Katrin Schneider · Mannheim, DE
• Benedikt Steitz · Macclesfield, GB
• Thomas Mueller · Hersbruck, DE
• Regina Reul · Mannheim, DE
• Constanze Obermiller · Heidelberg, DE
• Adivaraha Jayasankar · Naperville, US
• Michael R. Simon · Ann Arbor, US
• Yi Gao · Vernon Hills, US
• Harald Hach · Bad Bergzabern, DE
• Samuel Kyeremateng · Mannheim, DE
• Katharina Asmus · Hamburg, DE
• Ping Tong · Potomac, US
• Donghua Zhu · Vernon Hills, US
• Marius Naris · Downers Grove, US
• Colleen Garrett · Chicago, US

Key dates

• Filing date: Oct 16, 2019
• Grant date: Feb 15, 2022
• Expiry date: Oct 16, 2039

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K31/4985
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion.